Compass Pathways plc announced on March 18, 2025, the publication of results from its COMP004 study in the Journal of Clinical Psychiatry. This observational 52-week follow-up study evaluated COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD), building on previous Phase 2b trial findings.
The COMP004 study indicated that a single administration of 25 mg COMP360 psilocybin demonstrated a longer maintenance of antidepressant effects over a 52-week period compared to the 1 mg and 10 mg doses. These results reinforce earlier findings from the Phase 2b COMP001 trial, which showed a rapid and statistically significant reduction in depressive symptoms at three weeks, with durability up to 12 weeks.
This publication is significant as it provides further evidence of the potential for rapid and durable clinical benefits from a single administration of COMP360. The data supports the ongoing Phase 3 clinical development program and highlights COMP360's potential as a differentiated treatment option for the approximately 100 million people worldwide affected by TRD.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.